Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation by Barale, Cristina et al.
© Schattauer 2017 Thrombosis and Haemostasis 6/2017
1115Cellular Haemostasis and Platelets
Glucagon-like peptide 1-related peptides increase nitric oxide effects 
to reduce platelet activation
Cristina Barale1,2; Simona Buracco2; Franco Cavalot1,2; Chiara Frascaroli1,2; Angelo Guerrasio1,2; Isabella Russo1,2
1Internal Medicine and Metabolic Disease Unit, San Luigi Gonzaga Hospital, Turin, Italy; 2Department of Clinical and Biological Sciences of the Turin University, Turin, Italy
Summary
Glucagon-like peptide 1 (GLP-1) is object of intensive investigation for 
not only its metabolic effects but also the protective vascular actions. 
Since platelets exert a primary role in the pathogenesis of athero-
sclerosis, inflammation and vascular complications, we investigated 
whether GLP-1 directly influences platelet reactivity. For this purpose, 
in platelets from 72 healthy volunteers we evaluated GLP-1 receptor 
(GLP-1R) expression and the effects of a 15-minute incubation with 
the native form GLP-1(7–36), the N-terminally truncated form 
GLP-1(9–36) and the GLP-1 analogue Liraglutide (100 nmol/l) on: i) 
aggregation induced by collagen or arachidonic acid (AA); ii) platelet 
function under shear stress; iii) cGMP and cAMP synthesis and cGMP-
dependent protein kinase (PKG)-induced Vasodilator-Stimulated-
Phosphoprotein (VASP) phosphorylation; iv) activation of the signal-
ling molecules Phosphatidylinositol 3-Kinase (PI3-K)/Akt and Mitogen 
Activated Protein Kinase (MAPK)/ERK-1/2; and v) oxidative stress. Ex-
periments were repeated in the presence of the nitric oxide donor 
Na–nitroprusside. We found that platelets constitutively express 
GLP-1R and that, independently of GLP-1R, GLP-1(7–36), GLP-1(9–36) 
and Liraglutide exert platelet inhibitory effects as shown by: a) in-
creased NO-antiaggregating effects, b) increased the activation of the 
cGMP/PKG/VASP pathway, c) reduced the activation of PI3-K/Akt and 
MAPK/ERK-2 pathways, d) reduced the AA-induced oxidative stress. 
When the experiments were repeated in the presence of the antagon-
ist of GLP-1R Exendin(9–39), the platelet inhibitory effects were main-
tained, thus indicating a mechanism independent of GLP-1R. In con-
clusion, GLP-1(7–36), its degradation product GLP-1(9–36) and Lirag-
lutide exert similar inhibitory effects on platelet activation, suggesting 
a potential protective effect on the cardiovascular system.
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Introduction
The incretin hormone Glucagon-like peptide 1 (GLP-1), exerts a 
pivotal role in the maintenance of glucose homeostasis (1). It is 
principally secreted as GLP-1(7–36) amide, the biologically active 
circulating GLP-1 metabolite which, after binding to a specific 
GLP-1 receptor (GLP-1R), induces the increase of glucose-stimu-
lated insulin secretion. The biologic half-life of GLP-1(7–36) is 
very short since after secretion it is rapidly degraded by the 
enzyme dipeptidyl peptidase (DPP)-4 to GLP-1(9–36), the main 
GLP-1 metabolite in vivo which does not interact with GLP-1R (1).
In type 2 diabetes the incretin effect is deeply reduced (2) and 
the GLP-1-based therapies are now established as treatment op-
tions for the disease. Since type 2 diabetes therapy aims not only to 
improve the glycaemic homeostasis but also to prevent vascular 
complications, it is of the utmost interest to investigate if the “new 
drugs” introduced in clinical practice, like incretin mimetics, have 
a valuable impact on cardiovascular disease.
Interestingly, multiple actions of GLP-1 and the structurally re-
lated GLP-1R agonists are exerted on cells and tissues that do not 
express the classical GLP-1R (3). The evidence that the 
GLP-1(9–36) metabolite is also able to exert beneficial effects on 
the cardiovascular system suggests that some actions of the native 
GLP-1 could be exerted through a mechanism independent of 
GLP-1R (4). Actually, GLP-1(9–36) exerts cardiovascular actions 
like cardioprotection against the ischaemia-reperfusion injury, va-
sodilation (5–7), and activation of the nitric oxide (NO)/guano-
sine-3’,5’-cyclic monophosphate (cGMP) pathway in vascular en-
dothelium (8). Thus, GLP-1(9–36) cannot be considered an ‘inac-
tivated’ form of GLP-1 as previously thought.
Furthermore, previous studies suggest that GLP-1 metabolites 
and its long-acting analogues are able to decrease oxidative stress 
by increasing intracellular antioxidant defences and decreasing the 
reactive oxygen species (ROS) production through GLP-1R-de-
pendent and -independent pathways (9). Therefore, there is a 
strong rationale to verify whether GLP-1 influences platelets, cells 
deeply involved in the pathogenesis of atherosclerosis (10), par-
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ticularly of diabetic vascular complications, thus justifying a role 
for antiplatelet therapy both in secondary and in primary preven-
tion in diabetes mellitus (11).
The adhesion/aggregation process is regulated by the balance 
between pro- and anti-aggregating circulating agents such as NO. 
As well known, NO is involved in platelet anti-aggregation 
through the synthesis of cGMP and the consequent activation of 
the cGMP-dependent protein kinase (PKG): the cGMP/PKG sys-
tem modulates basic mechanisms of platelet activation (12). In-
hibitory effects exerted by exenatide alone – but not by either the 
native GLP-1(7–36) or the truncated GLP-1(9–36) – have been re-
cently shown in megakaryocyte cell line and platelets suggesting 
the ability of this GLP-1R agonist to directly influence platelet 
function (13).
However, the inability of GLP-1(7–36) and GLP-1(9–36) to in-
fluence per se platelet aggregation cannot exclude the possibility 
that GLP-1 peptides interfere with physiological antiaggregating 
agents such as NO and intracellular pathways that potentially 
could influence the cardiovascular system also by means of the 
platelet response.
Furthermore, the aim to specifically investigate the role of 
metabolically-inactive GLP-1(9–36) on cardiovascular function 
may contribute to explain the apparently disappointing results 
from some large-scale DPP-4 inhibitor trials that failed to demon-
strate any benefit on cardiovascular outcomes in patients affected 
by diabetes (14, 15), considering a possible reduced action of 
GLP-1(7–36) in addition to the inhibited production of 
GLP-1(9–36).
The present study was designed to examine the ability of GLP-1 
to influence in vitro platelet responses, their reactivity to NO and sig-
nalling molecules stimulated by pro-aggregating agents. We tested 
the effects of the native GLP-1(7–36), of the N-terminally truncated 
GLP-1(9–36) form and of the GLP-1 analogue Liraglutide.
Materials and methods
Chemicals
Collagen and arachidonic acid (AA) were purchased from Mascia 
Brunelli Spa (Monza, Milan, Italy). GLP-1(7–36), GLP-1(9–36) 
were obtained from DBA Italia Srl (Segrate, Milan, Italy). Liraglu-
tide (VICTOZA®) was obtained from Novo Nordisk (Glostrup, 
Denmark). The sources of the specific antibodies are shown in the 
different sections. The other reagents were obtained from Sigma 
(St. Louis, MO, USA). In the experiments, unless specified, we used 
100 nmol/l for GLP-1(7–36), GLP-1(9–36) and Liraglutide. This 
concentration is about to 5–10 times the concentrations detectable 
in incretin-based therapy (16) and, as known, higher drug concen-
trations are needed to obtain effects in vitro similar to those in vivo.
Subjects and platelet preparation
Seventy-two healthy volunteers (40 men/32 women; age: 24.6 ± 0.4 
years; body mass index [BMI]: 22.7 ± 0.7 kg/m2) were studied. The 
subjects were non smokers, normotensive, did not take any drug in 
the previous two weeks and showed normal range values also after 
oral glucose tolerance test. All exhibited normal insulin sensitivity 
(HOMA-IR: 1.7 ± 0.05). They gave informed consent before inves-
tigation and the Ethics Committee of our Hospital approved the 
study.
Fasting venous blood samples were anticoagulated with 3.8 % 
trisodium citrate (v/v: 1/9) or citrate-dextrose solution (ACD; v/v: 
1/6). Platelet-rich plasma (PRP) was obtained by using Platelet 
Function Centrifuge (BioData Corporation, Horsham, PA, USA). 
To prepare washed platelets (WP), ACD-anticoagulated PRP was 
processed as previously described (17).
Evaluation of GLP-1R
To evaluate the presence of GLP-1R on platelet surface flow cyto-
metry assays and western blot analyses were performed. WP were 
fixed, permeabilised and labelled with phycoerythrin (PE)-conju-
gated mouse monoclonal anti-Human GLP-1R (R&D Systems, 
Minneapolis, MN, USA). As a negative control, a PE Mouse IgG2b 
isotype control antibody (BioLegend, San Diego, CA, USA) was 
used at the same concentration as the (PE)-conjugated mouse 
monoclonal anti-Human GLP-1R. In addition, WP were labelled 
with allophycocyanin (APC)-conjugated mouse monoclonal anti-
Human Integrin α2b/CD41 (R&D Systems) as positive control for 
platelet identification. Analysis was carried out by using CyAn 
ADP Analyzer (Beckman Coulter, Brea, CA, USA).
For western blot analysis, WP samples were centrifuged and 
pellets dissolved in Laemmly buffer and processed as previously 
described (17). Membranes were incubated with mouse antibody 
anti-human GLP-1R and goat anti-Vinculin (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA). As secondary antibodies, we used, 
respectively, goat anti-mouse (Jackson ImmunoResearch, West 
Grove, PA, USA) and donkey anti-goat (SantaCruz Biotechnol-
ogy) conjugated to horseradish peroxidase. Blots were scanned 
and analysed densitometrically by the image analyzer 1D Image 
Analysis software (Kodak, Rochester, NY, USA). Pancreatic tissue 
(Santa Cruz Biotechnology) was used as positive control.
Platelet aggregation studies
Platelet aggregation studies were carried out in PRP by following 
light-scattering changes as described by Born (18) using a eight-
channel aggregation system (Platelet Aggregation Profiler, Model 
PAP-8, BioData Corporation). Platelet aggregation tests were car-
ried out after a 15-minute (min) preincubation with GLP-1(7–36), 
GLP-1(9–36) and Liraglutide with or without SNP (5 µmol/l, 5 
min) and induced by AA (0.5 mmol/l) or collagen (4 mg/l). Each 
aggregation test was recorded for 5 min and reported as maximal 
aggregation (MA).
Platelet reactivity in high shear-stress conditions
Whole blood (WB) samples were exposed to GLP-1(7–36), 
GLP-1(9–36), Liraglutide and platelet reactivity was evaluated by 
Platelet Function Analyzer (PFA-100, Siemens Healthcare Diag-
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nostic Products GmbH, Marburg, Germany) (19), measuring the 
time needed to form a platelet plug named “closure time” (sec-
onds), within an aperture cut into a platelet-reactive membrane 
coated with collagen plus epinephrine (CEPI). Tests were carried 
out also in the presence of SNP (20 µmol/l, 5 min).
cGMP and cAMP production
cGMP and cAMP were measured in PRP samples (500 µl) both in 
the absence and in the presence of a 20-min preincubation with 
the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine 
(IBMX) (100 µmol/l), then incubated with GLP-1(7–36), 
GLP-1(9–36), or Liraglutide for 15 min with or without SNP (5 
µmol/l, 5 min). Platelet samples were processed as previously de-
scribed (20). Some experiments were repeated after a preincu-
bation with the NO synthase (NOS) inhibitor NG-monomethyl-
L-arginine (L-NMMA) (1 mmol/l, 20 min), the soluble Guanylate 
Cyclase (sGC) inhibitor methylene blue (MB) (50 µmol/l, 20 min), 
or after exposure to AA (100 µmol/l, 8 min) with or without prein-
cubation with NADPH-oxidase inhibitor apocynin (10 µmol/l, 20 
min).
cGMP and cAMP were determined using cGMP and cAMP 
EIA kits (Abnova, Taipei City, Taiwan) according to the manufac-
turer’s instructions.
Signalling transduction molecule detection
To evaluate the influence of GLP-1 on the PKG/VASP pathway ac-
tivated by NO, WP were exposed to GLP-1(7–36), GLP-1(9–36) or 
Liraglutide, then stimulated by SNP (5 µmol/l, 5 min). To evaluate 
GLP-1 influence on PI3-K and MAPK pathways activation, WP 
were incubated with GLP-1(7–36), GLP-1(9–36) or Liraglutide, 
then activated by collagen (4 mg/l) or AA (100 µmol/l). Some ex-
periments were repeated after a 20-min preincubation with the 
GLP-1R antagonist Exendin(9–39) (100 nmol/l), the PKG in-
hibitor KT5823 (1 µmol/l) and the protein kinase A (PKA) in-
hibitor PKI (10 µmol/l). Then, samples were processed as de-
scribed above and membranes incubated with the following anti-
bodies: mouse anti-Akt, rabbit anti-phosphoAktSer-473 and mouse 
anti-phosphoERK-1/2Tyr-204,(Santa Cruz Biotechnology), rabbit 
anti-ERK1/2 (R&D Systems) and mouse anti-phosphoVASP-
ser-239 (Calbiochem–Merck Millipore, Darmstadt, Germany). As 
secondary antibodies we used goat anti-mouse and goat anti-rab-
bit (Santa Cruz Biotechnology).
ROS production
Intracellular ROS were evaluated in WP by using the sensitive flu-
orescent indicator 2’,7’-dihydrodichlorofluoresceine diacetate 
(DCF-DA), oxidised by H2O2 to the highly fluorescent DCF (21). 
WP (6×107 ml–1) were exposed to 10 µmol/l DCF-DA and incu-
bated for 15 min with GLP-1(7–36), GLP-1(9–36) or Liraglutide. 
AA was added just before measuring fluorescence. To examine the 
requirement for AA signalling events in ROS generation, platelets 
were preincubated for 20 min with the PI3-K inhibitors wortman-
nin (100 nmol/l) and LY294002 (100 µmol/l), the selective MAPK/
ERK-1/2 inhibitor U0126 (40 µmol/l), and the NADPH-oxidase 
inhibitors apocynin (10 µmol/l) and diphenyleniodonium (DPI) 
(10 µmol/l) and then exposed to GLP-1-related peptides. In addi-
tion, platelets were incubated with dihydroethidium (DHE) (20 
µmol/l), pelleted, rinsed, dissolved in phosphate-buffered saline, 
supplemented with calcium and fluorescence was measured to 
evaluate superoxide production.
Fluorescence was measured over a 60-min period at 1-min in-
tervals using a plate fluorometer (GloMax-Multi Detection Sys-
tem, Promega Corporation, Madison, WI, USA) fitted with 
490 nm excitation and 520 nm emission filters. Fluorescence per 
minute was first calculated for each sample, then ROS production 
was expressed as fold increase over basal values.
Statistical analysis
All values in the text and figures are expressed as mean ± SEM. 
Data were analysed using Student’s t-test, or one-way ANOVA fol-
lowed by post-hoc Bonferroni’s test. Results were significant when 
p<0.05.
Results
Expression of GLP-1R
As shown in ▶ Figure 1, analyses revealed appreciable levels of 
GLP-1R expression on platelet surface: actually, GLP-1R was de-
tected in 60 to 78 % (mean: 71.5 ± 1.8 %) of platelets by flow cyto-
metry assay (n=15) (A). Isotype control for the GLP1R antibody 
did not stain the sample.
Western blot (n=10) (B) showed that GLP-1R, expressed in 
pancreatic tissue as positive control, was consistently expressed 
also in platelets.
GLP-1 influence on platelet aggregation in PRP
In response to collagen (▶ Figure 2 A) or AA (▶ Figure 2 B) the 
antiaggregating effect of SNP was increased by GLP-1(7–36) 
(n=24), GLP-1(9–36) (n=24), and Liraglutide (n=24).
Notably, the GLP-1(7–36), GLP-1(9–36) and Liraglutide ac-
tions on the antiaggregating effects of SNP did not differ when pla-
telets were preincubated with Exendin(9–39) (n=24, p=NS for 
each), thus indicating that the ability of GLP-1(7–36), 
GLP-1(9–36) and Liraglutide to increase the antiaggregating ef-
fects of SNP occurred independently of GLP-1R. Quantitatively, 
after exposure to SNP: i) the aggregation to collagen decreased by 
34 ± 5 % and the addition of GLP-1(7–36), GLP-1(9–36) and Lir-
aglutide effectively decreased platelet aggregation by 59 ± 3 %, 57 ± 
3 % and 56 ± 3 %, respectively; ii) the aggregation to AA decreased 
by 36 ± 5 % with SNP, and the addition of GLP-1(7–36), 
GLP-1(9–36) and Liraglutide decreased platelet aggregation by 48 
± 3 %, 49 ± 5 % and 48 ± 4 %, respectively. Notably, the 
GLP-1(7–36), GLP-1(9–36) and Liraglutide actions on the antiag-
gregating effects of SNP did not differ when platelets were prein-
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cubated with the GLP-1R antagonist Exendin(9–39) (n=24, p=NS 
for each), thus indicating that the ability of GLP-1(7–36), 
GLP-1(9–36) and Liraglutide to increase the antiaggregating ef-
fects of SNP occurred independently of GLP-1R.
GLP-1 peptides alone did not modify platelet aggregation trig-
gered by collagen (84 ± 5 vs 91 ± 3 with GLP-1(7–36), vs 80 ± 4 
with GLP-1(9–36), vs 91 ± 4 with Liraglutide, n=12, p=NS for all) 
or by AA (86 ± 6 vs 82 ± 6 with GLP-1(7–36), vs 81 ± 5 with 
GLP-1(9–36), vs 92 ± 4 with Liraglutide, n=12, p=NS for all). Fur-
thermore, we also examined GLP-1 alone effects on platelet aggre-
gation at shorter time points (3–7 min) and lower concentrations 
(1–10 nmol/l) and no inhibitory effects were found (data not 
shown).
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Figure 1: Expression of 
GLP-1R on platelet sur-
face. Platelets were 
stained by PE-conjugated 
mouse anti-human 
GLP-1R specific mono-
clonal antibody and APC-
conjugated mouse mono-
clonal anti human inte-
grin α2b/CD41, and FACS 
assay analysis was per-
formed. The figure shows 
the single labelling for 
GLP-1R (PE) or CD41 
(APC) and the double 
 labelling dot plot 
GLP1-R(PE) + CD41(APC)) 
(n=15) (A). Western blot 
analysis of platelet 
samples from five differ-
ent subjects and of 
human pancreatic ex-
stract (HPE) sample as 
positive control. Blot is 
representative of platelet 
samples obtained from 
10 subjects (B).
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GLP-1 influence on platelet function evaluated by 
PFA-100 in WB
▶ Figure 2 C shows the GLP-1(7–36), GLP-1(9–36) and Liraglu-
tide effects on platelet adhesion and aggregation in WB measured 
by CEPI PFA-100. GLP-1-related peptides alone did not modify 
closure time. However, closure time was prolonged by SNP and it 
was further significantly increased when WB samples were prein-
cubated with GLP-1(7–36), GLP-1(9–36), and Liraglutide (n=6). 
The pretreatment with Exendin(9–39) did not alter the effects of 
GLP-1 peptides on closure time prolongation induced by SNP.
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Figure 2: GLP-1 effects 
on platelet aggre-
gation and PFA-100. 
Platelets were exposed 
for 15 min to 
GLP-1(7–36), 
GLP-1(9–36) and Liraglu-
tide (100 nmol/l) and 
their influence was evalu-
ated on the antiaggregat-
ing effects of the NO 
donor SNP (5 µmol/l) in 
response to collagen (4 
mg/l) (A) and AA (0.5 
mmol/l) (B) (n=24 per 
group) or PFA closure 
time with CEPI (collagen-
epinephrine cartridges) 
(n=6) (C), both in the ab-
sence and presence of the 
GLP-1 receptor antagon-
ist Exendin(9–39) (Exe) 
(100 nmol/l). ANOVA: 
p<0.0001, Bonferroni’s 
post-test: *p< 0.05 vs 
SNP alone, # p<0.05 vs 
basal.
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GLP-1 influence on cGMP/PKG/VASP pathway 
 activation
cGMP and cAMP production
In the presence of IBMX, GLP-1(7–36), GLP-1(9–36) and Liraglu-
tide alone did not significantly modify cGMP (n=12; p=NS vs 
basal values for each GLP-1 receptor agonist) (▶ Figure 3 A) or 
cAMP concentrations (n=6; p=NS vs basal values for each GLP-1 
receptor agonist) (▶ Figure 3 C). However, the cGMP synthesis in-
duced by SNP was significantly enhanced by a 15-min preincu-
bation with GLP-1(7–36), GLP-1(9–36) and Liraglutide, whereas 
cAMP levels showed a trend to increase in response to 
SNP+GLP-1 peptides, while not reaching statistical significance 
(n=6; p=NS vs basal values for each GLP-1 receptor agonist with 
or without SNP).
Furthermore, the effects of GLP-1(7–36), GLP-1(9–36) and Lir-
aglutide on NO-induced cGMP production: i) are not mediated by 
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Figure 3: GLP-1 effects 
on cGMP and cAMP. 
Platelets were exposed 
for 15-min to 
GLP-1(7–36), 
GLP-1(9–36) and Liraglu-
tide, and their effects 
were evaluated on the 
SNP-induced (5 µmol/l) 
cGMP levels both in ab-
sence and presence of Ex-
endin(9–39) (100 nmol/l), 
NO-synthase inhibitor 
L-NMMA (1 mmol/l), sGC 
inhibitor MB (50 µmol/l) 
(n=12 per group) (A) or 
AA (100 µmol/l) and the 
NADPH-oxidase inhibitor 
Apocynin (10 µmol/l) 
(n=6) (B). Platelets were 
exposed for 15 min to 
GLP-1(7–36), 
GLP-1(9–36) and Liraglu-
tide and their effects 
were evaluated (5 µmol/l) 
on cAMP levels both in 
the absence and presence 
of SNP (5 µmol/l) (n=6) 
(C). ANOVA: p<0.0001, 
Bonferroni’s post-
test:*p<0.05 vs SNP 
alone, #p<0.05 vs basal, 
unpaired Student’s test: § 
p<0.01 vs SNP, ** 
p<0.05 vs AA+SNP, 
***p<0.001 vs SNP, ## 
p<0.05 vs AA, §§ p<0.05 
vs AA+SNP.
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GLP-1R, since cGMP levels did not differ in the presence of Exen-
din(9–39) (n=12, p=NS for each); ii) are not mediated by NOS ac-
tivity, since cGMP levels were not different in the presence of the 
NOS inhibitor L-NMMA (n=12, p=NS for each); iii) are depend-
ent on sGC activity, since the sGC inhibitor MB suppressed cGMP 
levels induced by SNP alone (n=12, vs basal values p=NS for each) 
and SNP + GLP-1 peptides (n=12, vs SNP alone p=NS for each).
To clarify whether GLP-1 peptides can influence the NO-in-
duced cGMP production in conditions of augmented oxidative 
stress, platelets were preincubated with GLP-1 peptides, chal-
lenged with the proaggregant agent AA and stimulated by SNP 
(▶ Figure 3 B). AA decreased the SNP-induced cGMP production 
(46 %) and GLP-1 (7–36), GLP-1 (9–36) and Liraglutide produced 
a partial recovery (28 %, 31 % and 35 %, respectively). Since AA is 
known to activate NADPH-oxidase, the most important intracel-
lular source of superoxide anion, we tested the influence of the 
NADPH-oxidase inhibitor apocynin (10 µmol/l) on the reduction 
of NO-induced cGMP production exerted by AA. The preincu-
bation with apocynin determined a partial recovery of cGMP lev-
els measured in the presence of AA alone (50 %) or AA+SNP 
(57 %).
In the absence of IBMX, GLP-1 related peptides alone did not 
significantly modify cGMP concentrations (pmol/109 platelets) 
(from 3.5 ± 0.5 to 4.2 ± 0.5 with GLP-1(7–36), to 3.8 ± 0.1 with 
GLP-1(9–36) and to 4.0 ± 0.5 with Liraglutide; n=6, p=NS vs basal 
values for each). GLP-1 related peptides preserved their ability to 
increase cGMP levels stimulated by SNP: from 6.3 ± 0.5 with SNP 
(n=6; ANOVA: p<0.0001; Bonferroni’s post-hoc test: p<0.05 vs 
basal values) to 9.2 ± 0.6 with GLP-1(7–36)+SNP, to 9.8 ± 0.4 with 
GLP-1(9–36)+SNP and to 9.5 ± 0.5 with Liraglutide+SNP (n=6; 
ANOVA: p<0.0001; Bonferroni’s post-hoc test: p<0.05 vs SNP 
alone for each). cAMP levels were not affected by SNP, GLP-1 pep-
tides and SNP+GLP-1 peptides (data not shown).
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Figure 4: GLP-1 effects on VASP phosphorylation. Dose-dependent ef-
fects of a 15-min preincubation with GLP-1(7–36), GLP-1(9–36) and Liraglu-
tide (1–10–100 nmol/l) on VASP phosphorylation at Serine-239 (A) and in-
fluence of a 15-min preincubation with GLP-1(7–36), GLP-1(9–36) and Lirag-
lutide (100 nmol/l) on the SNP-induced VASP phosphorylation at Serine-239 
in the absence or in the presence of Exendin(9–39) (100 nmol/l) (B) and the 
PKG inhibitor KT5823 (1 µmol/l) (C) (n=10 for all). ANOVA: p<0.0001, Bon-
ferroni’s post-test:* p<0.05 vs basal, § p<0.05 vs SNP alone; Unpaired Stu-
dent’s test: # p< 0.0001 vs SNP alone or GLP-1 peptides+SNP.
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VASP phosphorylation at Serine-239
GLP-1(7–36), GLP-1(9–36) or Liraglutide modify per se the 
amount of VASP phosphorylated at Serine-239 (n=10, vs baseline 
p=NS) neither at concentrations lower than 100 nmol/l (1–10 
nmol/l) (▶ Figure 4 A) nor at shorter time points (data not 
shown). In the presence of SNP (n=10) a significant increase of 
pVASP-ser239 was observed and this was enhanced by 
GLP-1(7–36), GLP-1(9–36) and Liraglutide (▶ Figure 4 B, C). 
Quantitatively, after exposure to SNP, GLP-1(7–36), GLP-1(9–36) 
and Liraglutide further increased the SNP-induced pVASP by 44 ± 
5 %, 51 ± 7 % and 41 ± 8 %, respectively, without significant differ-
ences among GLP-1 peptides.
The preincubation with the PKG inhibitor KT5823 significantly 
reduced pVASP induced by SNP with GLP-1 peptides, whereas 
GLP-1(7–36), GLP-1(9–36) and Liraglutide effects did not differ in 
the presence of Exendin(9–39) (vs SNP+GLP-1 peptides p=NS).
GLP-1 influence on Collagen- and AA-induced 
 phosphorylation of Akt and ERK-1/2
GLP-1(7–36), GLP-1(9–36) or Liraglutide (n=10) similarly re-
duced the increased pAkt and pERK-2 amounts induced by col-
lagen (▶ Figure 5) or AA (▶ Figure 6). These effects were in-
fluenced neither by Exendin(9–39)(vs collagen+GLP-1 or 
AA+GLP-1 peptides p=NS) nor by the PKA inhibitor PKI (vs col-
lagen+GLP-1 or AA+GLP-1 peptides p=NS), thus indicating that 
GLP-1(7–36), GLP-1(9–36) or Liraglutide effects on pAkt and 
pERK-2 are not mediated by GLP-1R and do not involve PKA acti-
vation. Conversely, the effect of each GLP-1-related peptide was 
reduced after preincubation with KT5823, suggesting the involve-
ment of PKG in the ability of GLP-1 to interfere with the activation 
of PI3-K/Akt and MAPK/ERK-2 pathways stimulated by collagen 
or AA.
GLP-1 influence on ROS production
As shown in ▶ Figure 7, stimulation with 100 µmol/l AA led to an 
eight-fold increase in intracellular ROS production versus basal 
values (n=12, p<0.0001). Our results showed that AA-induced 
ROS production: i) involves PI3-K, since, in comparison to AA 
alone, wortmannin and LY294002 reduced ROS generation to a 
similar extent; ii) is more strictly dependent on the MAPK/ERK 
pathway because almost completely inhibited by U0126; iii) is at 
least partly mediated by NADPH-oxidase activity because simi-
larly inhibited by apocynin and DPI (▶ Figure 7 A).
When we investigated the influence of GLP-1 on ROS syn-
thesis, we found a reduction by 32 ± 4 % with GLP-1(7–36) (▶ Fig-
ure 7 B), 38 ± 7 % with GLP-1(9–36) (▶ Figure 7 C) and 40 ± 9 % 
with Liraglutide (▶ Figure 7 D) (n=12) without significant differ-
ences among the GLP-1 peptides. Similar results were obtained 
when we measured DHE oxydation as marker of superoxide pro-
duction: AA induced an increase on basal values of superoxide 
concentrations by 6 ± 1 (p<0.0001, n=6) that was reduced by 33 ± 
9 % with GLP-1 (7–36) (p<0.001, n=6), by 38 ± 11 % with GLP-1 
(9–36) (p<0.005, n=6) and by 40 ± 13 % with Liraglutide (p<0.001, 
n=6).
In order to verify the linkage between the inhibition of PI3-K, 
ERK-1/2 and NADPH-oxidase and GLP-1 effects on ROS, pla-
telets were pre-treated with the mentioned above inhibitors, incu-
bated with GLP-1(7–36), GLP-1(9–36), or Liraglutide and the ROS 
generation measured. Data indicate that the ability of 
GLP-1(7–36), GLP-1(9–36), or Liraglutide to further inhibit ROS 
production was lost in the presence of every inhibitor, thus sug-
gesting a complex signalling network regulating ROS production 
and influenced by the GLP-1-related peptide action.
Discussion
The main findings of this study were that platelet exposure to 
GLP-1: i) induced an increase of the NO-donor SNP ability to in-
hibit platelet aggregation, to stimulate cGMP production and to 
enhance the extent of phosphorylation of VASP-ser239; ii) reduced 
the activation of PI3-K/Akt and MAPK/ERK-2 pathways probably 
through a PKG-dependent mechanism; iii) reduced ROS produc-
tion. These results were similarly obtained in the presence of the 
native form GLP-1(7–36), the truncated peptide GLP-1(9–36), and 
the GLP-1 analogue Liraglutide.
This study describes an association between GLP-1 and platelet 
function by adding further information on GLP effects on the car-
diovascular system.
The main effects of GLP-1 on its target tissues, such as pancre-
atic islets, are mediated by GLP-1R. Human megakaryocytes ex-
press a functional GLP-1R (13) and in our study by western blot 
and flow cytometry assays we found that GLP-1R is also expressed 
on platelets; thus, we could hypothesise that the GLP-1R-depend-
ent pathway may be involved in the platelet effects of 
GLP-1(7–36). However, we observed that when platelets were pre-
incubated with Exendin(9–39), which functions as a specific 
GLP-1R antagonist, GLP-1 effects were preserved not only for 
GLP-1(9–36) but also for GLP-1(7–36) and Liraglutide, suggesting 
for both molecules a GLP-1R independent signalling. Fur-
thermore, in our study the effects of GLP-1 on the investigated as-
pects of platelet responses were not mediated by cAMP signalling, 
which is generally involved in the GLP-1R-mediated actions of 
GLP-1 (22). Our proposed schematic signalling involved in the 
GLP-1(7–36), GLP-1(9–36) and Liraglutide effects on platelets is 
summarised in ▶ Figure 8.
From the biochemical point of view, our original data show that 
platelet exposure to GLP-1 (7–36), GLP- (9–36) or Liraglutide 
even though alone does not exert direct effects on NO signalling, it 
increases the NO-induced activation of the cGMP/PKG/VASP 
pathway. In particular, we found that each GLP-1-related peptide 
amplifies to a similar extent the exogenous NO capability to in-
hibit platelet aggregation induced by different agonists; a possible 
explanation of this phenomenon could be an augmentation of 
NO-induced cGMP synthesis and consequent PKG activity, as 
mirrored by the increased levels of pVASP-ser239. Previous data 
suggested that GLP-1 can up-regulate endothelial NOS (eNOS) ac-
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Figure 5: GLP-1 effects on AKT and ERK-2 signalling. Platelets were ex-
posed for 15 min to GLP-1(7–36) (A), GLP-1(9–36) (B) and Liraglutide (C) 
(100 nmol/l) and evaluated for Akt and ERK-1/2 phosphorylation after stimu-
lation with collagen in the absence or in the presence of Exendin(9–39) (Exe) 
(100 nmol/l), the PKA inhibitor PKI (10 µmol/l) and the PKG inhibitor KT5823 
(KT) (1 µmol/l) (n=10 for all). Blots are representative of 10 independent ex-
periments. Unpaired Student’s test:*p< 0.05,**p<0.001,***p<0.0001.
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Figure 6: GLP-1 effects on AKT and ERK-2 signalling. Platelets were ex-
posed for 15 min platelet to GLP-1(7–36) (A), GLP-1(9–36) (B) and Liraglu-
tide (C) and evaluated for Akt and ERK-1/2 phosphorylation after stimulation 
with AA in the absence or in the presence of Exendin(9–39) (Exe) (100 
nmol/l), the PKA inhibitor PKI (10 µmol/l) and the PKG inhibitor KT5823 (KT) 
(1 µmol/l) (n=10 for all). Blots are representative of 10 independent experi-
ments. Unpaired Student’s test: *p< 0.01, **p<0.005, ***p<0.0001.
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Figure 7: GLP-1 effects on ROS production. ROS measurement (DCF-DA 
assay) in platelets stimulated by AA (100 µmol/l) in the absence and in the pres-
ence of a 20-min preincubation with: PI3-K inhibitors Wortmannin (100 nmol/l) 
and LY294002 (100 µmol/l), ERK-1/2 inhibitor U0126 (40 µmol/l), NADPH-oxidase 
inhibitors apocynin (10 µmol/l) and DPI (10 µmol/l) (n=12) (A). ANOVA: p<0.0001, 
Bonferroni’s post-test: *p<0.5 vs AA alone. Effects of a 15-min preincubation with 
GLP-1(7–36) (B), GLP-1(9–36) (C) and Liraglutide (100 nmol/l) (D) on platelet ROS 
production (DCF-DA assay) stimulated by AA (100 µmol/l) (n=6 for all) in the ab-
sence and in the presence of a-20 min preincubation with Wortmannin (100 
nmol/l), LY294002 (100 µmol/l), ERK-1/2 inhibitor U0126 (40 µmol/l), NADPH-ox-
idase inhibitors apocynin (10 µmol/l) and DPI (10 µmol/l). ANOVA: p<0.0001, Bon-
ferroni’s post-test:*p<0.5 vs AA alone; unpaired Student’s test: Wortmannin vs 
Wortmannin+GLP-1-related peptides, LY294002 vs LY294002+GLP-1-related 
peptides, U0126 vs U0126+GLP-1 related peptides, Apocynin vs Apocynin+GLP-1 
related peptides, DPI vs, DPI+GLP-1 related peptides =NS.
tivity and protein expression through the GLP-1R-dependent and 
GLP-1(9–36)-related pathways in vascular cells (8); furthermore, 
the GLP-1-induced NO synthesis and release via eNOS activation 
can explain the direct vasodilation by GLP-1 (23). Interestingly, 
Cameron et al. (13) found that the injury-induced thrombus 
formation in vivo was inhibited by the GLP-1R agonist exenatide 
although the same authors did not exclude the possibility that 
these effects could be mediated by endothelium. Surprisingly, they 
also demonstrated that exenatide – but not GLP-1 (7–36) – exerts 
antiaggregating effects on platelets without explaining the discrep-
ancy between these peptides which show similar affinity for 
GLP-1R. In our study, Liraglutide alone did not show any antiag-
gregating effect to AA and collagen.
In our study, we did not evaluate the direct influence of GLP-1 
on NOS activity. Thus, we cannot exclude a GLP-1 effect on NO 
synthesis. However, GLP-1(7–36), GLP-1(9–36) and Liraglutide 
per se did not significantly increase platelet cGMP and pVASP-
ser239 levels and their ability to enhance NO action on cGMP/
PKG/VASP pathway was not affected by the NOS inhibitor 
L-NMMA.
The ability of GLP-1(7–36), GLP-1(9–36) and Liraglutide to in-
crease the antiaggregating effects of NO was not restricted to 
stimulation by one agonist, but involved all platelet activators used 
in our study. This fact implies that the target site of GLP-1 was 
shared among many signalling pathways, rather than specific for a 
particular stimulant.
Present data show that GLP-1(7–36), GLP-1(9–36) or Liraglu-
tide significantly decreased the ROS production induced by AA 
which normally generates a variety of ROS essential for maximal 
platelet activation (24).
ROS generated by platelet activating agents act as second mess-
engers and might affect platelet function by reacting with NO. 
Therefore, ROS may partially modulate platelet function by at-
tenuating NO bioavailability via ONOO– generation (25) thus re-
ducing the activation of the cGMP/PKG/VASP pathway. The find-
ing that in our study GLP-1 attenuates oxidative stress and en-
hances the activation of cGMP/PKG/VASP by exogenous NO can 
What is known about this topic?
• Subjects affected by type 2 diabetes receiving GLP-1-based ther-
apy show a decreased number of cardiovascular events.
• The GLP-1 analogue exenatide exerts antiaggregating effects.
• Megakariocyte cells express GLP-1 receptor.
What does this paper add?
• Human platelets express GLP-1 receptor.
• The bioactive native GLP-1(7-36)amide, the GLP-1 analogue Lir-
aglutide but also the dipeptidyl peptidase 4-induced degradation 
product GLP-1(9-36)amide increase nitric oxide/cGMP/PKG/VASP 
and decrease PI/3K and MAPK/ERK-2 pathway activation in 
human platelets.
• GLP-1-related peptides reduce platelet oxidative stress.
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Figure 8: Schematic of 
proposed signalling in-
volved in GLP-1 effects 
on platelets. The 
scheme shows the GLP-
1-related peptides ability 
to influence platelet func-
tion by improving the NO 
inhibitory effects and at-
tenuating, via a PKG-me-
diated mechanism, the 
activation of PI3-K and 
MAPK signalling stimu-
lated by agonists. In this 
scenario, a role can be 
played by GLP-1 ability to 
interfere with the stimu-
lant-induced ROS produc-
tion and all these effects 
are independent of the 
known GLP-1 receptor 
(GLP-1R) which is ex-
pressed on platelet sur-
face.
induce to hypothesize that, in the last phenomenon, a role may be 
played by the increased NO bioavailability due to GLP-1-mediated 
ROS reduction.
We observed that the AA–induced increase of ROS was re-
duced by the ERK-1/2 inhibitor U0126, the PI3-K inhibitors wort-
mannin and LY294002, and the NOX inhibitors apocynin and DPI 
thus demonstrating a complex signalling networks, regulating 
ROS production. Noteworthy, ROS synthesis was almost com-
pletely blocked by the ERK-1/2 inhibitor U0126, to indicate that 
the MAPK/ERK-1/2 pathway is one of the major players in intra-
cellular production of ROS by AA. Nevertheless, when using the 
mentioned above specific inhibitors in the presence of GLP-1, 
their inhibitory effects on ROS production were not enhanced, 
thus suggesting a putative role for MAPK/ERK, and an involve-
ment of the PI3-K and NADPH-oxidase pathways on the capabil-
ity of GLP-1 related peptides to reduce ROS production.
When we investigated the influence of GLP-1 on the agonist-in-
duced PI3-K/Akt and MAPK/ERK-1/2 signalling activation, we 
found that GLP-1(7–36), GLP-1(9–36) and Liraglutide reduced to 
a similar extent both Akt and ERK-2 activation stimulated by AA 
or collagen.
Altogether, MAPK/ERK-1/2 and PI3-K/Akt regulate platelet 
functions (26, 27) even if the role of MAPK/ERK-1/2 activation 
pathway on platelet aggregation is controversial (28). Our findings 
also confirmed the evidence of a crosstalk between PI3-K/Akt and 
ERK-2 activated by collagen and AA since the PI3-K inhibitor 
wortmannin abolished not only Akt but also ERK-2 phosphory-
lation (data not shown).
We found that the effects of GLP-1(7–36), GLP-1(9–36) and 
Liraglutide on the agonist-induced pAkt and pERK-2 levels were 
significantly reduced by the PKG inhibitor KT5823 whereas they 
were not affected by the PKA inhibitor PKI. These data could sug-
gest that GLP-1 effects are mediated by PKG whereas the adenylate 
cyclase-cAMP-PKA pathway is not involved.
To explain the relationship between the PI3-K and MAPK 
pathways and PKG, it is important to underline that an activation 
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In conclusion, collectively, this study reports that the GLP-1 di-
rectly influences platelet function and suggests a potential protec-
tive role on the cardiovascular system.
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of sGC may also be directed by agonists (29). Actually, it has been 
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lated by agonists, NO promotes platelet activating signalling, 
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crease, thus promoting PKG inhibitory effects. However, this hy-
pothesis needs to be confirmed by more extensive experiments.
In our study, the effects of GLP-1(7–36) and GLP-1(9–36) were 
very similar to those observed with Liraglutide, and also in the last 
case the pathway involved could be GLP-1(9–36)-related. Actually, 
data from Literature suggest that GLP-1(9–36) is responsible for 
some anti-atherogenic effects of Liraglutide rather than the intact 
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might be mediated through a distinct receptor for GLP-1(9–36) 
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lutide and at high risk for cardiovascular events had lower rates of 
cardiovascular events and death from any cause than did those in 
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